Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Novel AML treament approaches

Fabio Guolo • 10 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Antibodies CAR-T CPX-351 Cytarabine Daunorubicin Gemtuzumab ozogamicin Gilteritinib Midostaurin

Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, discusses novel acute myeloid leukemia (AML) therapies such as gemtuzumab ozogamicin and CPX-351, as well as the onset of trials investigating CAR-T and BiTEs for this patient population. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Fabio Guolo

1:25
Low bone marrow cellularity predicts hematologic AEs to CPX-351 in AML
Fabio Guolo • 10 Dec 2023
2:55
Post-transplant PD1 blockade plus autologous lymphocytes in R/R HL
Fabio Guolo • 10 Dec 2023
1:30
Evaluating the optimal duration of CPX-351 treatment & best timing for alloSCT consolidation in AML
Fabio Guolo • 10 Dec 2023
2:26
Prognostic relevance of a BPDCN-like immunophenotype in cytogenetically normal AML
Fabio Guolo • 11 Jun 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals